ALK and lung adenocarcinoma: To our knowledge, this is the largest cohort of patients in which ALK rearrangements have been evaluated by a fully-automated immunochemistry assay in patients with early-stage lung adenocarcinoma, unlike most other ALK-related studies focusing on late-stage patients.